Orphan drug talks and midnight meetings under Japan-EMA collaborations
This article was originally published in SRA
When Junko Sato, Japan's international liaison officer at the European Medicines Agency in London, started trying to convince her regulatory colleagues back home to expand the scope of the discussions they have with their EU counterparts on drugs for treating rare diseases, she had her work cut out.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.